 Bichun Ouyang
Concepts (285)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 17 | 2022 | 1180 | 1.570 |
Why?
| | Cerebral Hemorrhage | 11 | 2022 | 141 | 1.330 |
Why?
| | Fragile X Syndrome | 5 | 2020 | 178 | 1.090 |
Why?
| | Deep Brain Stimulation | 6 | 2022 | 76 | 1.020 |
Why?
| | Female | 61 | 2022 | 18253 | 0.820 |
Why?
| | Male | 59 | 2022 | 17583 | 0.820 |
Why?
| | Stroke | 6 | 2018 | 367 | 0.800 |
Why?
| | Intracranial Aneurysm | 4 | 2014 | 88 | 0.800 |
Why?
| | Safety-net Providers | 1 | 2019 | 9 | 0.750 |
Why?
| | Hospitals, Public | 1 | 2019 | 31 | 0.750 |
Why?
| | Sarcoidosis | 1 | 2019 | 15 | 0.740 |
Why?
| | Central Nervous System Diseases | 1 | 2019 | 23 | 0.740 |
Why?
| | Aged | 43 | 2022 | 10295 | 0.700 |
Why?
| | Humans | 69 | 2022 | 31481 | 0.700 |
Why?
| | Aneurysm, Ruptured | 2 | 2014 | 27 | 0.650 |
Why?
| | Middle Aged | 39 | 2022 | 11209 | 0.630 |
Why?
| | Subthalamic Nucleus | 4 | 2022 | 36 | 0.620 |
Why?
| | Hallucinations | 3 | 2011 | 94 | 0.610 |
Why?
| | Diffusion Magnetic Resonance Imaging | 5 | 2022 | 115 | 0.590 |
Why?
| | Retrospective Studies | 23 | 2021 | 3591 | 0.560 |
Why?
| | Self-Help Groups | 1 | 2014 | 8 | 0.560 |
Why?
| | Thrombolytic Therapy | 3 | 2016 | 85 | 0.550 |
Why?
| | Ataxia | 3 | 2020 | 79 | 0.540 |
Why?
| | Fibrinolytic Agents | 3 | 2011 | 99 | 0.540 |
Why?
| | Cholesterol | 1 | 2014 | 68 | 0.540 |
Why?
| | Length of Stay | 6 | 2018 | 377 | 0.540 |
Why?
| | Thrombectomy | 3 | 2021 | 51 | 0.530 |
Why?
| | Social Media | 1 | 2014 | 35 | 0.520 |
Why?
| | Tremor | 3 | 2020 | 136 | 0.520 |
Why?
| | Subarachnoid Hemorrhage | 4 | 2016 | 95 | 0.500 |
Why?
| | Severity of Illness Index | 10 | 2020 | 1240 | 0.490 |
Why?
| | Biostatistics | 1 | 2012 | 6 | 0.490 |
Why?
| | Bayes Theorem | 1 | 2012 | 36 | 0.480 |
Why?
| | Seizures | 3 | 2019 | 88 | 0.480 |
Why?
| | Brain Ischemia | 3 | 2021 | 122 | 0.470 |
Why?
| | Heart Transplantation | 1 | 2012 | 50 | 0.470 |
Why?
| | Adult | 23 | 2021 | 9779 | 0.460 |
Why?
| | Health Facilities | 1 | 2011 | 11 | 0.450 |
Why?
| | Risk Factors | 14 | 2021 | 2664 | 0.440 |
Why?
| | Hematoma, Subdural, Acute | 3 | 2017 | 12 | 0.430 |
Why?
| | Hospital Mortality | 4 | 2017 | 192 | 0.430 |
Why?
| | Databases, Factual | 4 | 2022 | 391 | 0.430 |
Why?
| | Glucosylceramidase | 2 | 2022 | 22 | 0.420 |
Why?
| | Postoperative Complications | 4 | 2018 | 1083 | 0.390 |
Why?
| | Young Adult | 10 | 2021 | 2277 | 0.390 |
Why?
| | Accidental Falls | 3 | 2020 | 118 | 0.380 |
Why?
| | Gait | 4 | 2020 | 395 | 0.380 |
Why?
| | Cognition Disorders | 4 | 2021 | 1075 | 0.360 |
Why?
| | Treatment Outcome | 15 | 2021 | 3910 | 0.350 |
Why?
| | Disease Progression | 1 | 2011 | 861 | 0.340 |
Why?
| | Aged, 80 and over | 18 | 2021 | 5234 | 0.340 |
Why?
| | Parkinsonian Disorders | 2 | 2021 | 210 | 0.330 |
Why?
| | Brain | 5 | 2021 | 1655 | 0.320 |
Why?
| | Gait Disorders, Neurologic | 2 | 2020 | 150 | 0.320 |
Why?
| | Predictive Value of Tests | 5 | 2021 | 637 | 0.310 |
Why?
| | Patient Transfer | 2 | 2017 | 24 | 0.310 |
Why?
| | Illinois | 3 | 2019 | 266 | 0.300 |
Why?
| | Quality of Life | 3 | 2020 | 663 | 0.300 |
Why?
| | Neuropsychological Tests | 5 | 2022 | 1300 | 0.290 |
Why?
| | Trinucleotide Repeat Expansion | 3 | 2020 | 43 | 0.290 |
Why?
| | Biopsy | 2 | 2019 | 283 | 0.290 |
Why?
| | Time Factors | 8 | 2020 | 1902 | 0.280 |
Why?
| | Magnetic Resonance Imaging | 3 | 2022 | 1273 | 0.270 |
Why?
| | Fragile X Mental Retardation Protein | 3 | 2020 | 107 | 0.270 |
Why?
| | Hematoma, Subdural | 2 | 2015 | 13 | 0.270 |
Why?
| | Heterozygote | 2 | 2022 | 115 | 0.260 |
Why?
| | Hospitalization | 3 | 2020 | 359 | 0.260 |
Why?
| | Prospective Studies | 10 | 2021 | 1934 | 0.250 |
Why?
| | Spinal Fusion | 3 | 2018 | 464 | 0.250 |
Why?
| | Attention | 3 | 2020 | 163 | 0.240 |
Why?
| | Prognosis | 4 | 2020 | 1028 | 0.240 |
Why?
| | Postural Balance | 2 | 2021 | 127 | 0.240 |
Why?
| | Psychometrics | 2 | 2014 | 287 | 0.240 |
Why?
| | Cerebral Amyloid Angiopathy | 3 | 2019 | 101 | 0.240 |
Why?
| | Physical Therapists | 1 | 2022 | 4 | 0.240 |
Why?
| | Child, Preschool | 4 | 2021 | 786 | 0.240 |
Why?
| | Case-Control Studies | 8 | 2020 | 687 | 0.240 |
Why?
| | Blood Pressure Determination | 1 | 2022 | 22 | 0.230 |
Why?
| | Executive Function | 3 | 2018 | 109 | 0.230 |
Why?
| | Arterial Pressure | 1 | 2022 | 16 | 0.230 |
Why?
| | Weather | 2 | 2019 | 18 | 0.230 |
Why?
| | Tissue Plasminogen Activator | 3 | 2011 | 80 | 0.230 |
Why?
| | Psychomotor Performance | 2 | 2020 | 258 | 0.220 |
Why?
| | Medical Futility | 1 | 2021 | 2 | 0.220 |
Why?
| | Leukoaraiosis | 1 | 2021 | 7 | 0.220 |
Why?
| | Multidetector Computed Tomography | 1 | 2021 | 12 | 0.220 |
Why?
| | Mutation | 2 | 2022 | 464 | 0.210 |
Why?
| | Longitudinal Studies | 6 | 2021 | 1452 | 0.210 |
Why?
| | Martial Arts | 1 | 2020 | 5 | 0.210 |
Why?
| | Tomography, X-Ray Computed | 5 | 2018 | 891 | 0.210 |
Why?
| | Hyperglycemia | 1 | 2020 | 49 | 0.200 |
Why?
| | Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.200 |
Why?
| | Adolescent | 8 | 2021 | 2667 | 0.200 |
Why?
| | Nootropic Agents | 1 | 2020 | 14 | 0.200 |
Why?
| | Decompression, Surgical | 2 | 2018 | 146 | 0.190 |
Why?
| | Blood Glucose | 1 | 2020 | 137 | 0.190 |
Why?
| | Arm | 1 | 2020 | 78 | 0.190 |
Why?
| | Odds Ratio | 4 | 2017 | 327 | 0.190 |
Why?
| | Huntington Disease | 1 | 2020 | 61 | 0.190 |
Why?
| | Radiography, Thoracic | 1 | 2019 | 39 | 0.190 |
Why?
| | Vagus Nerve Stimulation | 1 | 2019 | 8 | 0.190 |
Why?
| | Depression | 2 | 2016 | 516 | 0.180 |
Why?
| | Microelectrodes | 1 | 2018 | 41 | 0.180 |
Why?
| | Electrodes, Implanted | 1 | 2018 | 44 | 0.180 |
Why?
| | Cognition | 3 | 2022 | 1206 | 0.180 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 100 | 0.170 |
Why?
| | Movement Disorders | 1 | 2020 | 150 | 0.170 |
Why?
| | Middle Cerebral Artery | 1 | 2018 | 22 | 0.170 |
Why?
| | Population Surveillance | 1 | 2019 | 127 | 0.170 |
Why?
| | Tertiary Care Centers | 2 | 2015 | 82 | 0.170 |
Why?
| | Walking | 1 | 2020 | 249 | 0.170 |
Why?
| | Carotid Artery, Internal | 1 | 2018 | 31 | 0.170 |
Why?
| | Intraoperative Neurophysiological Monitoring | 1 | 2017 | 14 | 0.170 |
Why?
| | Phenotype | 1 | 2019 | 379 | 0.170 |
Why?
| | Pilot Projects | 4 | 2022 | 455 | 0.170 |
Why?
| | Lumbosacral Region | 1 | 2018 | 71 | 0.170 |
Why?
| | Health Status Disparities | 1 | 2018 | 70 | 0.160 |
Why?
| | Cerebral Ventriculitis | 1 | 2017 | 4 | 0.160 |
Why?
| | Meningitis, Aseptic | 1 | 2017 | 6 | 0.160 |
Why?
| | Meningitis, Bacterial | 1 | 2017 | 9 | 0.160 |
Why?
| | Lactic Acid | 1 | 2017 | 20 | 0.160 |
Why?
| | Corpus Striatum | 1 | 2018 | 116 | 0.160 |
Why?
| | Ventriculostomy | 1 | 2017 | 11 | 0.160 |
Why?
| | Arterial Occlusive Diseases | 1 | 2017 | 21 | 0.160 |
Why?
| | Dopamine | 1 | 2018 | 162 | 0.160 |
Why?
| | Disability Evaluation | 5 | 2021 | 332 | 0.160 |
Why?
| | Fever | 1 | 2017 | 38 | 0.160 |
Why?
| | Sex Characteristics | 1 | 2018 | 128 | 0.160 |
Why?
| | Unemployment | 1 | 2016 | 3 | 0.160 |
Why?
| | Antidepressive Agents | 1 | 2017 | 108 | 0.160 |
Why?
| | Epilepsy | 1 | 2017 | 109 | 0.150 |
Why?
| | Anxiety Disorders | 1 | 2017 | 176 | 0.150 |
Why?
| | Nervous System Diseases | 1 | 2017 | 145 | 0.140 |
Why?
| | Depressive Disorder | 1 | 2017 | 212 | 0.140 |
Why?
| | Substantia Nigra | 1 | 2016 | 157 | 0.140 |
Why?
| | Diskectomy | 1 | 2018 | 181 | 0.140 |
Why?
| | Cohort Studies | 4 | 2018 | 2014 | 0.140 |
Why?
| | alpha-Synuclein | 1 | 2016 | 147 | 0.140 |
Why?
| | Anxiety | 1 | 2016 | 162 | 0.140 |
Why?
| | Child | 4 | 2021 | 1572 | 0.130 |
Why?
| | Lung Diseases | 1 | 2015 | 54 | 0.130 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 50 | 0.130 |
Why?
| | Logistic Models | 5 | 2017 | 479 | 0.130 |
Why?
| | African Americans | 1 | 2021 | 818 | 0.130 |
Why?
| | Cervical Vertebrae | 1 | 2018 | 343 | 0.130 |
Why?
| | Vascular Access Devices | 1 | 2013 | 9 | 0.130 |
Why?
| | Respiration, Artificial | 1 | 2015 | 116 | 0.130 |
Why?
| | Cerebral Arteries | 1 | 2013 | 37 | 0.130 |
Why?
| | Neoplasms | 1 | 2016 | 280 | 0.120 |
Why?
| | Cerebral Angiography | 1 | 2013 | 72 | 0.120 |
Why?
| | Stochastic Processes | 1 | 2012 | 15 | 0.120 |
Why?
| | Lumbar Vertebrae | 1 | 2018 | 469 | 0.120 |
Why?
| | Anterior Temporal Lobectomy | 1 | 2012 | 11 | 0.120 |
Why?
| | Menopause, Premature | 1 | 2012 | 7 | 0.120 |
Why?
| | Graft Rejection | 1 | 2012 | 84 | 0.120 |
Why?
| | Models, Statistical | 1 | 2012 | 144 | 0.110 |
Why?
| | Epilepsy, Temporal Lobe | 1 | 2012 | 48 | 0.110 |
Why?
| | Cerebrovascular Disorders | 1 | 2013 | 123 | 0.110 |
Why?
| | Health Facility Size | 1 | 2011 | 3 | 0.110 |
Why?
| | Arrhythmias, Cardiac | 1 | 2013 | 158 | 0.110 |
Why?
| | Injections, Intravenous | 1 | 2011 | 61 | 0.110 |
Why?
| | Drug Utilization | 1 | 2011 | 27 | 0.110 |
Why?
| | International Classification of Diseases | 1 | 2011 | 25 | 0.110 |
Why?
| | Ischemic Attack, Transient | 1 | 2011 | 27 | 0.110 |
Why?
| | Confidence Intervals | 1 | 2011 | 102 | 0.110 |
Why?
| | Temporal Lobe | 1 | 2012 | 112 | 0.110 |
Why?
| | Radiography | 4 | 2015 | 717 | 0.110 |
Why?
| | Cholecystokinin | 1 | 2011 | 9 | 0.110 |
Why?
| | Communication Disorders | 1 | 2011 | 5 | 0.110 |
Why?
| | Circle of Willis | 1 | 2011 | 8 | 0.110 |
Why?
| | Certification | 1 | 2011 | 60 | 0.110 |
Why?
| | Mental Status Schedule | 1 | 2011 | 121 | 0.110 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2010 | 5 | 0.110 |
Why?
| | Incidence | 3 | 2019 | 829 | 0.110 |
Why?
| | Estrogen Replacement Therapy | 1 | 2010 | 22 | 0.110 |
Why?
| | Referral and Consultation | 1 | 2011 | 99 | 0.100 |
Why?
| | Vitamin B Deficiency | 1 | 2010 | 1 | 0.100 |
Why?
| | Vitamin B Complex | 1 | 2010 | 6 | 0.100 |
Why?
| | Chicago | 3 | 2021 | 955 | 0.100 |
Why?
| | Medication Errors | 1 | 2010 | 20 | 0.100 |
Why?
| | Feasibility Studies | 2 | 2022 | 281 | 0.100 |
Why?
| | Reference Values | 2 | 2021 | 260 | 0.100 |
Why?
| | Prevalence | 4 | 2013 | 544 | 0.100 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2011 | 332 | 0.100 |
Why?
| | Sleep | 1 | 2013 | 357 | 0.090 |
Why?
| | Atmospheric Pressure | 2 | 2019 | 12 | 0.090 |
Why?
| | Brain Infarction | 1 | 2009 | 78 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 1 | 2011 | 462 | 0.090 |
Why?
| | Circadian Rhythm | 1 | 2012 | 305 | 0.090 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 580 | 0.090 |
Why?
| | Hypertension | 3 | 2018 | 283 | 0.080 |
Why?
| | Age Factors | 3 | 2017 | 943 | 0.080 |
Why?
| | Risk Assessment | 3 | 2017 | 806 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2019 | 2028 | 0.070 |
Why?
| | Alleles | 2 | 2020 | 221 | 0.070 |
Why?
| | Multivariate Analysis | 2 | 2017 | 390 | 0.070 |
Why?
| | Range of Motion, Articular | 2 | 2020 | 703 | 0.070 |
Why?
| | False Positive Reactions | 2 | 2017 | 40 | 0.070 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 178 | 0.060 |
Why?
| | Recovery of Function | 2 | 2018 | 309 | 0.060 |
Why?
| | Comorbidity | 2 | 2017 | 562 | 0.060 |
Why?
| | Alzheimer Disease | 1 | 2014 | 1829 | 0.060 |
Why?
| | Survivors | 2 | 2015 | 68 | 0.060 |
Why?
| | Genetic Testing | 2 | 2014 | 73 | 0.060 |
Why?
| | Radial Artery | 1 | 2022 | 17 | 0.060 |
Why?
| | Blindness | 1 | 2022 | 15 | 0.060 |
Why?
| | Atrophy | 1 | 2021 | 108 | 0.050 |
Why?
| | Blood Pressure | 1 | 2022 | 260 | 0.050 |
Why?
| | Delivery of Health Care | 1 | 2022 | 130 | 0.050 |
Why?
| | Spatio-Temporal Analysis | 1 | 2020 | 4 | 0.050 |
Why?
| | Time and Motion Studies | 1 | 2020 | 13 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2020 | 82 | 0.050 |
Why?
| | Foot | 1 | 2020 | 35 | 0.050 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2019 | 2 | 0.050 |
Why?
| | Critical Pathways | 1 | 2018 | 23 | 0.050 |
Why?
| | Temperature | 1 | 2018 | 85 | 0.050 |
Why?
| | Personal Satisfaction | 1 | 2018 | 52 | 0.040 |
Why?
| | Independent Living | 1 | 2021 | 257 | 0.040 |
Why?
| | Diabetes Complications | 1 | 2018 | 74 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 42 | 0.040 |
Why?
| | Acute Kidney Injury | 1 | 2018 | 64 | 0.040 |
Why?
| | Putamen | 1 | 2018 | 24 | 0.040 |
Why?
| | Biomechanical Phenomena | 1 | 2020 | 719 | 0.040 |
Why?
| | Cameroon | 1 | 2017 | 2 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2017 | 11 | 0.040 |
Why?
| | Hospitals, Urban | 1 | 2017 | 37 | 0.040 |
Why?
| | Morbidity | 1 | 2017 | 71 | 0.040 |
Why?
| | United States | 2 | 2018 | 2539 | 0.040 |
Why?
| | Myocardial Infarction | 1 | 2018 | 187 | 0.040 |
Why?
| | Spinal Puncture | 1 | 2017 | 23 | 0.040 |
Why?
| | Body Temperature Regulation | 1 | 2017 | 25 | 0.040 |
Why?
| | Olfactory Bulb | 1 | 2016 | 13 | 0.040 |
Why?
| | Locus Coeruleus | 1 | 2016 | 24 | 0.040 |
Why?
| | Myocardial Ischemia | 1 | 2017 | 63 | 0.040 |
Why?
| | Serotonin Uptake Inhibitors | 1 | 2017 | 90 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2016 | 156 | 0.040 |
Why?
| | Motor Activity | 1 | 2020 | 397 | 0.040 |
Why?
| | Electroencephalography | 1 | 2017 | 145 | 0.040 |
Why?
| | Anticonvulsants | 1 | 2017 | 110 | 0.040 |
Why?
| | Educational Status | 1 | 2017 | 291 | 0.040 |
Why?
| | Registries | 1 | 2017 | 214 | 0.040 |
Why?
| | Glasgow Coma Scale | 1 | 2015 | 18 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2017 | 559 | 0.040 |
Why?
| | Inpatients | 1 | 2017 | 154 | 0.040 |
Why?
| | Heart Failure | 1 | 2018 | 232 | 0.040 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2016 | 386 | 0.030 |
Why?
| | Infant | 1 | 2017 | 642 | 0.030 |
Why?
| | Probability | 1 | 2014 | 104 | 0.030 |
Why?
| | Ventilator Weaning | 1 | 2015 | 33 | 0.030 |
Why?
| | Space Perception | 1 | 2014 | 45 | 0.030 |
Why?
| | Language | 1 | 2014 | 79 | 0.030 |
Why?
| | False Negative Reactions | 1 | 2013 | 16 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 2015 | 70 | 0.030 |
Why?
| | Magnetic Resonance Angiography | 1 | 2013 | 51 | 0.030 |
Why?
| | Troponin I | 1 | 2013 | 21 | 0.030 |
Why?
| | Sleep Stages | 1 | 2013 | 41 | 0.030 |
Why?
| | Patient Discharge | 1 | 2015 | 163 | 0.030 |
Why?
| | Memory Disorders | 1 | 2014 | 181 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2015 | 316 | 0.030 |
Why?
| | Neurosurgical Procedures | 1 | 2015 | 169 | 0.030 |
Why?
| | Electrocardiography | 1 | 2013 | 209 | 0.030 |
Why?
| | Models, Economic | 1 | 2011 | 10 | 0.030 |
Why?
| | Decision Trees | 1 | 2011 | 19 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2011 | 25 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2011 | 55 | 0.030 |
Why?
| | Social Behavior Disorders | 1 | 2011 | 5 | 0.030 |
Why?
| | Gene Frequency | 1 | 2011 | 80 | 0.030 |
Why?
| | Language Disorders | 1 | 2011 | 12 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2011 | 153 | 0.030 |
Why?
| | Memory | 1 | 2013 | 343 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2011 | 90 | 0.030 |
Why?
| | Smoking | 1 | 2012 | 202 | 0.030 |
Why?
| | Drug Dosage Calculations | 1 | 2010 | 7 | 0.030 |
Why?
| | Vitamin B 6 | 1 | 2010 | 4 | 0.030 |
Why?
| | Vitamin B 12 | 1 | 2010 | 12 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 89 | 0.030 |
Why?
| | Diet Surveys | 1 | 2010 | 26 | 0.030 |
Why?
| | Folic Acid | 1 | 2010 | 24 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 986 | 0.020 |
Why?
| | HIV Infections | 1 | 2017 | 951 | 0.020 |
Why?
| | Body Weight | 1 | 2010 | 167 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 423 | 0.020 |
Why?
| | Sex Factors | 1 | 2011 | 542 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 512 | 0.020 |
Why?
| | Chronic Disease | 1 | 2010 | 544 | 0.020 |
Why?
|
|
Ouyang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|